I don't think that the cash spend is going to be too much going...

I don't think that the cash spend is going to be too much going forward.

The company stated that the MHRA will decide which device classification Vitrogro will be classed as, not if it is a device or not. So no clinical trials will be needed there.

Trials will be needed to sell in the US, but that will be funded by income imho.

Another big cost will be producing more stock, but if we need to do that it will be because we would have sold the existing mountain of stock, so there will be funds a plenty then.

However if more cash are needed, I'm sure they will use the non-dilutive funding options offered by our partner.

cheers

ps. pleased to hear about the $1.20 valuation.